Chiron Refining GMP Remediation Plan Following FDA Warning Letter

The FDA letter requests additional information on "investigations into cGMP deviations and the design and conduct of studies to aid investigations," Chiron says. The letter follows an inspection of Chiron's Liverpool facility where Fluvirin is produced.